Wire · opportunities
US FDA approves Roivant-Priovant's skin and muscle disease drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The US FDA approved Lisraya, the first oral drug for dermatomyositis, a rare disease affecting skin and muscles, developed by Roivant and Priovant Therapeutics. The drug reduces the need for steroids and improves both skin and muscle symptoms, impacting fewer than 5,000 people in the US.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 28 Aug 2026 and 7 Sep 2026.
◆ ◆ The Wire takeaway
You can now access a rare disease market with a new oral drug that reduces steroid use and improves patient outcomes. This approval opens the door for competitors in rare skin and muscle disease treatment to innovate beyond injection or infusion therapies.
◆ Coverage
6 sources · first reported 28 Aug 2026 · latest 7 Sep 2026
◆ Related on Wire
◆ Topics